OncoMatch/Clinical Trials/NCT03425526
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Is NCT03425526 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes for hematopoietic and lymphoid cell neoplasm.
Treatment: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes — This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: corticosteroid (prednisone)
Exception: ≤ 0.1 mg/kg/day at time of enrollment
Patients receiving prednisone > 0.1 mg/kg/day or equivalent at time of enrollment
Cannot have received: anti-thymocyte globulin (ATG)
Exception: not received within 14 days
have received anti-thymocyte globulin (ATG) within 14 days
Cannot have received: donor lymphocyte infusion (DLI)
Exception: not received within 28 days
have received donor lymphocyte infusion (DLI) within 28 days of enrollment
Cannot have received: anti-CD52 antibody (Campath)
Exception: not received within 28 days
have received Campath within 28 days of enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03425526 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior corticosteroid, anti-thymocyte globulin, donor lymphocyte infusion disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify